Gedeon Richter Exceeds FY25 Estimates, Raises Guidance

Key Financial Highlights

Gedeon Richter Plc announced fiscal year 2025 results that surpassed analyst expectations, with pharmaceutical revenues reaching HUF914 billion. The company reported a 14% growth in clean EBIT on a constant exchange rate basis, outperforming its previous guidance of 8% to 10%.

Segment Performance Overview

The strong performance was driven by significant growth in the women's healthcare and biosimilars divisions. The women's healthcare segment posted a 14.8% year-over-year growth, while the biosimilars division saw a 19% revenue increase. The company's key product, Vraylar, also continued its positive trajectory.

Economic and Market Impact

For fiscal year 2026, Gedeon Richter has issued guidance for high single-digit constant exchange rate growth in both pharmaceutical revenues and clean EBIT. This positive outlook is set despite an anticipated 5 percentage point headwind from foreign exchange rates, signaling confidence in its core operations.

Summary and Outlook

Gedeon Richter's robust FY25 results and optimistic FY26 forecast indicate strong operational momentum. Future growth will be supported by new biosimilar launches, including ustekinumab, and continued expansion of key brands like Ryeqo and Drovelis.

FAQ

Q: What were Gedeon Richter's key achievements in fiscal year 2025?
A: The company surpassed revenue and EBIT expectations, driven by strong growth in its women's healthcare and biosimilars segments.

Q: What is the company's outlook for fiscal year 2026?
A: Gedeon Richter forecasts high single-digit growth in both revenue and clean EBIT on a constant exchange rate basis.

Source: Investing.com